Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

ABSTRACT AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Full description

Bibliographic Details
Main Authors: Tyler Brady, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L. Roe, Kuishu Ren, Kim Rosenthal, Patrick M. McTamney, Michael E. Abram, Katie Streicher, Elizabeth J. Kelly
Format: Article
Language:English
Published: American Society for Microbiology 2022-10-01
Series:Microbiology Spectrum
Subjects:
severe acute respiratory syndrome coronavirus 2
coronavirus disease 2019
monoclonal antibody
spike protein
receptor binding domain
Online Access:https://journals.asm.org/doi/10.1128/spectrum.01034-22

Internet

https://journals.asm.org/doi/10.1128/spectrum.01034-22

Similar Items